Page last updated: 2024-08-01 18:56:13
astatine
Description
Astatine: Astatine. A radioactive halogen with the atomic symbol At, and atomic number 85. Its isotopes range in mass number from 200 to 219 and all have an extremely short half-life. Astatine may be of use in the treatment of hyperthyroidism because it emits ALPHA PARTICLES. [MeSH]
diastatine : no description available [CHeBI]
Cross-References
Synonyms (13)
| Synonym |
|---|
| at |
| CHEBI:30414 |
| diastatine |
| 7440-68-8 |
| 31665-25-5 |
| astatine |
| astatanylastatine |
| xi595hal7h , |
| unii-xi595hal7h |
| helvetium |
| astatine [mi] |
| alabamine |
| Q27113553 |
Drug Classes (1)
Research
Studies (304)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 57 (18.75) | 18.7374 |
| 1990's | 64 (21.05) | 18.2507 |
| 2000's | 86 (28.29) | 29.6817 |
| 2010's | 78 (25.66) | 24.3611 |
| 2020's | 19 (6.25) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (0.31%) | 5.53% |
| Reviews | 28 (8.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 298 (91.13%) | 84.16% |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Abnormalities, Autosome | 0 | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Acute Disease | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Acute Myelogenous Leukemia | 0 | | 1982 | 2022 | 28.3 | low | 0 | 2 | 0 | 0 | 0 | 1 |
| Adenocarcinoma | 0 | | 1983 | 2022 | 25.2 | low | 0 | 3 | 3 | 3 | 0 | 2 |
| Adenocarcinoma Of Kidney | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Adenocarcinoma, Basal Cell | 0 | | 1983 | 2022 | 25.2 | low | 0 | 3 | 3 | 3 | 0 | 2 |
| Adenocarcinoma, Papillary | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adenofibroma | 0 | | 1967 | 1967 | 57.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Adrenal Cancer | 0 | | 1964 | 1964 | 60.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Anaplastic Astrocytoma | 0 | | 2003 | 2008 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Anaplastic Oligodendroglioma | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Androgen-Independent Prostatic Cancer | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Angiogenesis, Pathologic | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Animal Mammary Carcinoma | 0 | | 1964 | 1964 | 60.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Arachnoidal Cerebellar Sarcoma, Circumscribed | 0 | | 1995 | 2004 | 24.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Arsenic Encephalopathy | 0 | | 1973 | 1973 | 51.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Ascites | 0 | | 1981 | 2015 | 29.0 | low | 0 | 2 | 1 | 0 | 1 | 0 |
| Astrocytoma | 0 | | 2003 | 2008 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Astrocytoma, Grade IV | 0 | | 1999 | 2013 | 18.7 | low | 0 | 0 | 1 | 4 | 1 | 0 |
| ATLL | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Atrophy | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| B-Cell Lymphoma | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| B16 Melanoma | 0 | | 1988 | 1989 | 35.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Benign Cerebellar Neoplasms | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Benign Meningeal Neoplasms | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Benign Neoplasms | 0 | | 1958 | 2021 | 23.3 | low | 0 | 8 | 6 | 9 | 11 | 1 |
| Benign Neoplasms, Brain | 0 | | 1999 | 2020 | 15.4 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| Bladder Cancer | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Body Weight | 0 | | 1971 | 2021 | 21.0 | low | 0 | 1 | 0 | 0 | 1 | 1 |
| Bone Cancer | 0 | | 1994 | 2020 | 22.2 | low | 0 | 0 | 3 | 0 | 1 | 0 |
| Bone Neoplasms | 0 | | 1994 | 2020 | 22.2 | low | 0 | 0 | 3 | 0 | 1 | 0 |
| Bovine Diseases | 0 | | 1973 | 1973 | 51.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Brain Neoplasms | 0 | | 1999 | 2020 | 15.4 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| Breast Cancer | 0 | | 2006 | 2016 | 14.2 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| Breast Neoplasms | 0 | | 2006 | 2016 | 14.2 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| Cancer of Colon | 0 | | 1991 | 2014 | 20.3 | low | 0 | 0 | 1 | 4 | 1 | 0 |
| Cancer of Head | 0 | | 2005 | 2007 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Cancer of Kidney | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cancer of Liver | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Lung | 0 | | 2002 | 2018 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Cancer of Ovary | 0 | | 1981 | 2017 | 18.6 | low | 1 | 2 | 2 | 8 | 6 | 0 |
| Cancer of Pancreas | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Pituitary | 0 | | 1964 | 1967 | 58.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Cancer of Prostate | 0 | | 2008 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Cancer of Rectum | 0 | | 1983 | 1994 | 35.8 | low | 0 | 2 | 2 | 0 | 0 | 0 |
| Cancer of Skin | 0 | | 1992 | 1996 | 29.0 | low | 0 | 0 | 4 | 0 | 0 | 0 |
| Cancer of Stomach | 0 | | 1992 | 2021 | 17.8 | low | 0 | 0 | 2 | 0 | 1 | 1 |
| Cancer of Testis | 0 | | 1964 | 1971 | 56.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Cancer of the Thyroid | 0 | | 1986 | 2022 | 21.6 | low | 0 | 2 | 1 | 2 | 0 | 2 |
| Cancer of the Uterus | 0 | | 1964 | 1991 | 46.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Cancer, Radiation-Induced | 0 | | 1964 | 1967 | 58.0 | low | 0 | 3 | 0 | 0 | 0 | 0 |
| Carcinoma | 0 | | 1967 | 2015 | 30.2 | low | 0 | 2 | 0 | 1 | 1 | 0 |
| Carcinoma, Anaplastic | 0 | | 1967 | 2015 | 30.2 | low | 0 | 2 | 0 | 1 | 1 | 0 |
| Carcinoma, Ehrlich Tumor | 0 | | 1990 | 2004 | 27.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Carcinoma, Epidermoid | 0 | | 2003 | 2011 | 17.7 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| Carcinoma, Non-Small Cell Lung | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Non-Small-Cell Lung | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Renal Cell | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Carcinoma, Squamous Cell | 0 | | 2003 | 2011 | 17.7 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| Carcinomatous Meningitis | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cell Transformation, Neoplastic | 0 | | 2016 | 2017 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Choriocarcinoma | 0 | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Chromosome-Defective Micronuclei | 0 | | 2003 | 2014 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Cirrhosis | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Colonic Neoplasms | 0 | | 1991 | 2014 | 20.3 | low | 0 | 0 | 1 | 4 | 1 | 0 |
| Colorectal Cancer | 0 | | 2001 | 2005 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Colorectal Neoplasms | 0 | | 2001 | 2005 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Cyst | 0 | | 1954 | 1954 | 70.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Diffuse Mixed Small and Large Cell Lymphoma | 0 | | 2000 | 2015 | 18.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| Disease Models, Animal | 0 | | 1993 | 2014 | 19.4 | low | 0 | 0 | 3 | 3 | 3 | 0 |
| Embolism | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Embolus | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Epidermal Cyst | 0 | | 1952 | 1954 | 71.0 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Experimental Leukemia | 0 | | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Experimental Mammary Neoplasms | 0 | | 1964 | 2003 | 47.8 | low | 0 | 3 | 0 | 1 | 0 | 0 |
| Experimental Neoplasms | 0 | | 1958 | 2011 | 36.4 | low | 0 | 6 | 2 | 2 | 1 | 0 |
| Experimental Radiation Injuries | 0 | | 1998 | 2009 | 22.3 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| Eye Diseases | 0 | | 1954 | 1954 | 70.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Eye Disorders | 0 | | 1954 | 1954 | 70.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Fibrosis | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Germinoblastoma | 0 | | 1987 | 1998 | 30.3 | low | 0 | 1 | 2 | 0 | 0 | 0 |
| Glial Cell Tumors | 0 | | 1989 | 2021 | 20.5 | low | 0 | 1 | 4 | 5 | 1 | 1 |
| Glioblastoma | 0 | | 1999 | 2013 | 18.7 | low | 0 | 0 | 1 | 4 | 1 | 0 |
| Glioblastoma with Sarcomatous Component | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Glioma | 0 | | 1989 | 2021 | 20.5 | low | 0 | 1 | 4 | 5 | 1 | 1 |
| Gliosarcoma | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Granulocytic Leukemia | 0 | | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Head and Neck Neoplasms | 0 | | 2005 | 2007 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Hematologic Malignancies | 0 | | 2012 | 2018 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Hematologic Neoplasms | 0 | | 2012 | 2018 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Hyperplasia | 0 | | 1971 | 1971 | 53.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypertrophy | 0 | | 1971 | 1971 | 53.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Injuries, Radiation | 0 | | 1996 | 2011 | 20.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| Interstitial Cell Tumor | 0 | | 1971 | 1971 | 53.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Kahler Disease | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Kidney Diseases | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Kidney Neoplasms | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Leucocythaemia | 0 | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Leukemia | 0 | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Leukemia-Lymphoma, Adult T-Cell | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leukemia, Myeloid | 0 | | 1982 | 1982 | 42.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Leukemia, Myeloid, Acute | 0 | | 1982 | 2022 | 28.3 | low | 0 | 2 | 0 | 0 | 0 | 1 |
| Liver Diseases | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Dysfunction | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Neoplasms | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Local Neoplasm Recurrence | 0 | | 2008 | 2023 | 7.0 | low | 0 | 0 | 0 | 1 | 1 | 2 |
| Lung Neoplasms | 0 | | 2002 | 2018 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Lymph Node Metastasis | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Lymphoma | 0 | | 1987 | 1998 | 30.3 | low | 0 | 1 | 2 | 0 | 0 | 0 |
| Lymphoma, B-Cell | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphoma, Non-Hodgkin | 0 | | 2000 | 2015 | 18.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| Malignant Melanoma | 0 | | 1986 | 1999 | 29.2 | low | 0 | 1 | 12 | 0 | 0 | 0 |
| Medulloblastoma | 0 | | 1995 | 2004 | 24.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Melanoma | 0 | | 1986 | 1999 | 29.2 | low | 0 | 1 | 12 | 0 | 0 | 0 |
| Meningeal Carcinomatosis | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Meningeal Neoplasms | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Meningitis | 0 | | 1994 | 1996 | 29.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Mercury Poisoning | 0 | | 1973 | 1973 | 51.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Metastase | 0 | | 1990 | 2013 | 23.4 | low | 0 | 0 | 3 | 1 | 1 | 0 |
| Micrometastases, Neoplasm | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Minimal Disease, Residual | 0 | | 2015 | 2019 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Multiple Myeloma | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple Primary Neoplasms | 0 | | 1964 | 1964 | 60.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Necrosis | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neoplasm Metastasis | 0 | | 1990 | 2013 | 23.4 | low | 0 | 0 | 3 | 1 | 1 | 0 |
| Neoplasms | 0 | | 1958 | 2021 | 23.3 | low | 0 | 8 | 6 | 9 | 11 | 1 |
| Neuroblastoma | 0 | | 1995 | 2022 | 22.4 | low | 0 | 0 | 4 | 0 | 0 | 1 |
| Oligodendroglioma | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Osteogenic Sarcoma | 0 | | 1994 | 1998 | 28.7 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| Osteosarcoma | 0 | | 1994 | 1998 | 28.7 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| Ovarian Neoplasms | 0 | | 1981 | 2017 | 18.6 | low | 1 | 2 | 2 | 8 | 6 | 0 |
| Pachymeningitis | 0 | | 1994 | 1996 | 29.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Pancreatic Neoplasms | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Peritoneal Carcinomatosis | 0 | | 1990 | 2015 | 24.8 | low | 0 | 0 | 3 | 0 | 1 | 0 |
| Peritoneal Neoplasms | 0 | | 1990 | 2015 | 24.8 | low | 0 | 0 | 3 | 0 | 1 | 0 |
| Pheochromocytoma | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pheochromocytoma, Extra-Adrenal | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pituitary Neoplasms | 0 | | 1964 | 1967 | 58.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Plasma Cell Tumor | 0 | | 1982 | 1998 | 34.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Plasmacytoma | 0 | | 1982 | 1998 | 34.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Poisoning | 0 | | 1973 | 1973 | 51.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Poisoning, Mercury | 0 | | 1973 | 1973 | 51.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Prostatic Neoplasms | 0 | | 2008 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Prostatic Neoplasms, Castration-Resistant | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Rectal Neoplasms | 0 | | 1983 | 1994 | 35.8 | low | 0 | 2 | 2 | 0 | 0 | 0 |
| Rhabdomyosarcoma | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Sarcoma, Synovial | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sensitivity and Specificity | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Skin Neoplasms | 0 | | 1992 | 1996 | 29.0 | low | 0 | 0 | 4 | 0 | 0 | 0 |
| Stomach Neoplasms | 0 | | 1992 | 2021 | 17.8 | low | 0 | 0 | 2 | 0 | 1 | 1 |
| Synovioma | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Testicular Neoplasms | 0 | | 1964 | 1971 | 56.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| Thyroid Diseases | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Thyroid Neoplasms | 0 | | 1986 | 2022 | 21.6 | low | 0 | 2 | 1 | 2 | 0 | 2 |
| Urinary Bladder Neoplasms | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Uterine Neoplasms | 0 | | 1964 | 1991 | 46.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| Weight Gain | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
[Investigator-Initiated Clinical Trial of 211At-NaAt against Refractory Thyroid Cancer].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 49, Issue:8, 2022
Comparison of the Therapeutic Effects of [International journal of molecular sciences, , Aug-21, Volume: 23, Issue:16, 2022
Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein.Nuclear medicine and biology, , Volume: 33, Issue:4, 2006
Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.Nuclear medicine and biology, , Volume: 31, Issue:8, 2004
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.European journal of nuclear medicine and molecular imaging, , Volume: 29, Issue:7, 2002
The development of a [211At]-astatinated endoradiotherapeutic drug: Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies.International journal of radiation oncology, biology, physics, , Apr-30, Volume: 29, Issue:1, 1994
Endogenous 211At alpha-particle radiotherapy for undifferentiated thyroid cancer.Acta radiologica. Supplementum, , Volume: 376, 1991
Tissue dose estimates following the selective uptake of 125IUdR and other radiolabelled thymidine precursors in resistant tumours.The British journal of radiology, , Volume: 64, Issue:757, 1991
Relative concentration of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, , Volume: 13, Issue:3, 1988
Biodistribution of 6-[211At]astato-2-methyl-1,4-naphthoquinol bis(diphosphate salt) and 211At- in mice with a transplanted rectal adenocarcinoma.The International journal of applied radiation and isotopes, , Volume: 35, Issue:9, 1984
alpha-Particle track autoradiography for localization of a 211At-astatinated drug.Experientia, , Mar-15, Volume: 39, Issue:3, 1983
Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention.Anticancer research, , Volume: 23, Issue:2B
α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 56, Issue:11, 2015
The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study.Acta oncologica (Stockholm, Sweden), , Volume: 39, Issue:6, 2000
211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y.International journal of radiation oncology, biology, physics, , Volume: 10, Issue:3, 1984
Astatine-211--tellurium radiocolloid cures experimental malignant ascites.Science (New York, N.Y.), , Apr-17, Volume: 212, Issue:4492, 1981
Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.Anticancer research, , Volume: 20, Issue:1A
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 49, Issue:1, 2008
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.European journal of nuclear medicine and molecular imaging, , Volume: 30, Issue:10, 2003
Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.European journal of nuclear medicine and molecular imaging, , Volume: 47, Issue:1, 2020
211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 40, Issue:7, 1999
Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.British journal of cancer, , Volume: 69, Issue:6, 1994
Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.Radiation research, , Volume: 139, Issue:2, 1994
Labeling Monoclonal Antibody with α-emitting Cancer biotherapy & radiopharmaceuticals, , Volume: 35, Issue:7, 2020
Systemic treatment with 4-211Atphenylalanine enhances survival of rats with intracranial glioblastoma.Nuklearmedizin. Nuclear medicine, , Dec-13, Volume: 52, Issue:6, 2013
Synthesis and analysis of 2-[211At]-L-phenylalanine and 4-[211At]-L-phenylalanine and their uptake in human glioma cell cultures in-vitro.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, , Volume: 68, Issue:6, 2010
Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.European journal of nuclear medicine and molecular imaging, , Volume: 35, Issue:9, 2008
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 49, Issue:1, 2008
Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 54, Issue:4, 2002
211At-alpha-dose dependence of poly-ADP-ribosylation of human glioblastoma cells in vitro. Suitability in cancer therapy?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], , Volume: 175, Issue:9, 1999
The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.Nuclear medicine and biology, , Volume: 43, Issue:1, 2016
The advantage of antibody cocktails for targeted alpha therapy depends on specific activity.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 55, Issue:12, 2014
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.Nuclear medicine and biology, , Volume: 36, Issue:6, 2009
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-01, Volume: 14, Issue:3, 2008
In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.Nuclear medicine and biology, , Volume: 33, Issue:3, 2006
Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.Oncology reports, , Volume: 15, Issue:3, 2006
Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.PloS one, , Volume: 10, Issue:5, 2015
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.Cancer biotherapy & radiopharmaceuticals, , Volume: 20, Issue:5, 2005
Relative concentration of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, , Volume: 13, Issue:3, 1988
Construction of a growth curve for mammary tumors of the rat.Cancer research, , Volume: 27, Issue:8, 1967
Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells.Anticancer research, , Volume: 24, Issue:6
Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.Anticancer research, , Volume: 20, Issue:1A
Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas.Nuclear medicine and biology, , Volume: 38, Issue:1, 2011
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 72, Issue:1, 2008
Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 67, Issue:1, 2007
Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.The Laryngoscope, , Volume: 117, Issue:6, 2007
In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.European journal of nuclear medicine and molecular imaging, , Volume: 32, Issue:11, 2005
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.European journal of nuclear medicine and molecular imaging, , Volume: 30, Issue:5, 2003
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.European journal of nuclear medicine and molecular imaging, , Volume: 30, Issue:10, 2003
Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.Cancer biotherapy & radiopharmaceuticals, , Volume: 29, Issue:6, 2014
Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein.Nuclear medicine and biology, , Volume: 33, Issue:4, 2006
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.Cancer biotherapy & radiopharmaceuticals, , Volume: 20, Issue:5, 2005
Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.Nuclear medicine and biology, , Volume: 31, Issue:8, 2004
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.European journal of nuclear medicine and molecular imaging, , Volume: 29, Issue:7, 2002
Tissue dose estimates following the selective uptake of 125IUdR and other radiolabelled thymidine precursors in resistant tumours.The British journal of radiology, , Volume: 64, Issue:757, 1991
Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay.Anticancer research, , Volume: 18, Issue:3A
Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention.Anticancer research, , Volume: 23, Issue:2B
In vitro effects of free 211At,211At-albumin and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines.Anticancer research, , Volume: 20, Issue:2A
Systemic treatment with 4-211Atphenylalanine enhances survival of rats with intracranial glioblastoma.Nuklearmedizin. Nuclear medicine, , Dec-13, Volume: 52, Issue:6, 2013
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 49, Issue:1, 2008
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 72, Issue:1, 2008
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.European journal of nuclear medicine and molecular imaging, , Volume: 29, Issue:7, 2002
Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 54, Issue:4, 2002
211At-alpha-dose dependence of poly-ADP-ribosylation of human glioblastoma cells in vitro. Suitability in cancer therapy?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], , Volume: 175, Issue:9, 1999
Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy.Journal of nanobiotechnology, , Jul-28, Volume: 19, Issue:1, 2021
Labeling Monoclonal Antibody with α-emitting Cancer biotherapy & radiopharmaceuticals, , Volume: 35, Issue:7, 2020
Synthesis and analysis of 2-[211At]-L-phenylalanine and 4-[211At]-L-phenylalanine and their uptake in human glioma cell cultures in-vitro.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, , Volume: 68, Issue:6, 2010
Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 67, Issue:1, 2007
In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 44, Issue:11, 2003
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.European journal of nuclear medicine and molecular imaging, , Volume: 30, Issue:5, 2003
Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells.Nuclear medicine and biology, , Volume: 29, Issue:7, 2002
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.Radiation research, , Volume: 149, Issue:2, 1998
Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.Nuclear medicine and biology, , Volume: 24, Issue:3, 1997
Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.International journal of radiation biology, , Volume: 72, Issue:1, 1997
Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide.Nuclear medicine and biology, , Volume: 22, Issue:4, 1995
Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.Proceedings of the National Academy of Sciences of the United States of America, , Volume: 86, Issue:18, 1989
The development of a [211AT]-astatinated endoradiotherapeutic drug: part IV--late radiation effects.International journal of radiation oncology, biology, physics, , Mar-15, Volume: 40, Issue:5, 1998
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma.NCI monographs : a publication of the National Cancer Institute, , Issue:3, 1987
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.Medical physics, , Volume: 42, Issue:7, 2015
Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation.International journal of radiation biology, , Volume: 78, Issue:2, 2002
Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.British journal of cancer, , Volume: 83, Issue:10, 2000
Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers.Peptides, , Volume: 25, Issue:12, 2004
Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.Journal of neuro-oncology, , Volume: 25, Issue:1, 1995
Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor.Bioconjugate chemistry, , Volume: 17, Issue:1
Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience.Hybridoma, , Volume: 18, Issue:1, 1999
The survival of monolayers of cells growing in clusters irradiated by 211At appended to the cell surfaces.Radiation research, , Volume: 151, Issue:6, 1999
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.Radiation research, , Volume: 149, Issue:2, 1998
Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.International journal of radiation biology, , Volume: 72, Issue:1, 1997
[211At]methylene blue for targeted radiotherapy of human melanoma xenografts: dose fractionation in the treatment of cutaneous tumours.European journal of cancer (Oxford, England : 1990), , Volume: 32A, Issue:7, 1996
Radioiodinated methylene blue for diagnosing early melanoma metastases.Lancet (London, England), , Sep-14, Volume: 348, Issue:9029, 1996
211At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage.European journal of cancer (Oxford, England : 1990), , Volume: 32A, Issue:11, 1996
Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide.Nuclear medicine and biology, , Volume: 22, Issue:4, 1995
211At-methylene blue in targeted radiotherapy of disseminated melanoma.Pigment cell research, , Volume: 7, Issue:5, 1994
Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.British journal of cancer, , Volume: 69, Issue:6, 1994
211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases.Cancer research, , Aug-15, Volume: 52, Issue:16, 1992
211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases.Cancer research, , May-15, Volume: 50, Issue:10, 1990
Astatine-211: its possible applications in cancer therapy.International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes, , Volume: 37, Issue:8, 1986
Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-astatobenzoate: comparisons in vivo with the p-[125I]iodobenzoyl conjugate.Bioconjugate chemistry, , Volume: 2, Issue:3
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.Cancer research, , Sep-01, Volume: 54, Issue:17, 1994
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.Blood, , May-02, Volume: 121, Issue:18, 2013
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.Cancer biotherapy & radiopharmaceuticals, , Volume: 20, Issue:5, 2005
Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.Australasian radiology, , Volume: 43, Issue:4, 1999
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases.Cancer research, , May-15, Volume: 50, Issue:10, 1990
[no title available]Molecular pharmaceutics, , 09-06, Volume: 18, Issue:9, 2021
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.Cancer biotherapy & radiopharmaceuticals, , Volume: 35, Issue:6, 2020
An Appendix of Radionuclides Used in Targeted Alpha Therapy.Journal of medical imaging and radiation sciences, , Volume: 50, Issue:4 Suppl 1, 2019
Astatine-211 imaging by a Compton camera for targeted radiotherapy.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, , Volume: 139, 2018
Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 59, Issue:4, 2018
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Expert opinion on biological therapy, , Volume: 16, Issue:8, 2016
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.Scientific reports, , Jul-14, Volume: 5, 2015
Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.Cancer biotherapy & radiopharmaceuticals, , Volume: 28, Issue:1, 2013
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.Current radiopharmaceuticals, , Volume: 4, Issue:4, 2011
Astatine-211: production and availability.Current radiopharmaceuticals, , Volume: 4, Issue:3, 2011
Effect of different cell cluster models on the radiobiological output for (211)At-radioimmunotherapy.Cancer biotherapy & radiopharmaceuticals, , Volume: 26, Issue:1, 2011
The ARRONAX project.Current radiopharmaceuticals, , Volume: 4, Issue:3, 2011
Evaluating 99mTc Auger electrons for targeted tumor radiotherapy by computational methods.Medical physics, , Volume: 37, Issue:7, 2010
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.Nuclear medicine and biology, , Volume: 34, Issue:7, 2007
Potential and pitfalls of therapy with alpha-particles.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 46, Issue:8, 2005
Radioimmunotherapy with alpha-particle emitting radionuclides.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., , Volume: 48, Issue:4, 2004
External targets for the production of 211At--review and status of the target development at the Hannover cyclotron.Zeitschrift fur medizinische Physik, , Volume: 14, Issue:3, 2004
A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides.Acta oncologica (Stockholm, Sweden), , Volume: 43, Issue:3, 2004
Overcoming the obstacles to clinical evaluation of (211)At-labeled radiopharmaceuticals.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 42, Issue:10, 2001
Advancements in cancer therapy with alpha-emitters: a review.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 51, Issue:1, 2001
Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.European journal of nuclear medicine, , Volume: 28, Issue:4, 2001
Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.Current pharmaceutical design, , Volume: 6, Issue:14, 2000
Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.Australasian radiology, , Volume: 43, Issue:4, 1999
Genetic enhancement of radionuclide cancer therapy.Lancet (London, England), , Dec-04, Volume: 354, Issue:9194, 1999
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, , Volume: 141, 1996
Targeted therapy using alpha emitters.Physics in medicine and biology, , Volume: 41, Issue:10, 1996
Steps towards cancer therapy with radionuclides--a review including radiation biophysical aspects.Radiobiologia, radiotherapia, , Volume: 31, Issue:3, 1990
A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy.International journal of radiation oncology, biology, physics, , Volume: 13, Issue:11, 1987
Astatine-211: its possible applications in cancer therapy.International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes, , Volume: 37, Issue:8, 1986
Therapeutic applications of Auger and alpha emitting radionuclides.Strahlentherapie, , Volume: 160, Issue:12, 1984
Radioactive derivatives of 2-methyl-1, 4-naphthoquinol bis (diphosphate salt) as anti-cancer drugs with high LET radiations.Progress in clinical and biological research, , Volume: 166, 1984
Radiation biology and potential therapeutic applications of radionuclides.Bulletin du cancer, , Volume: 67, Issue:3, 1980
Potential future application with therapeutic agents.Seminars in nuclear medicine, , Volume: 9, Issue:2, 1979
TUMOR INDUCTION WITH ASTATINE-211 IN RATS: CHARACTERIZATION OF PITUITARY TUMORS.Cancer research, , Volume: 24, 1964
The induction of tumors in the rat by astatine-211.Radiation research, , Volume: 9, Issue:3, 1958
Two ways to establish potential At-211 radiopharmaceuticals.Anticancer research, , Volume: 17, Issue:3B
1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.Bioconjugate chemistry, , Volume: 3, Issue:6
[Leukemia & lymphoma, , Volume: 64, Issue:7
Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives.Bioconjugate chemistry, , Volume: 15, Issue:3
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , 09-15, Volume: 28, Issue:18, 2022
Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.British journal of cancer, , Volume: 77, Issue:12, 1998
3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.British journal of cancer, , Volume: 76, Issue:2, 1997
Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.Nuclear medicine and biology, , Volume: 23, Issue:6, 1996
Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.Journal of neuro-oncology, , Volume: 25, Issue:1, 1995
1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.Bioconjugate chemistry, , Volume: 3, Issue:6
Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 58, Issue:4, 2017
Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.PloS one, , Volume: 10, Issue:5, 2015
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.International journal of radiation oncology, biology, physics, , Nov-01, Volume: 93, Issue:3, 2015
Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.Cancer biotherapy & radiopharmaceuticals, , Volume: 28, Issue:2, 2013
Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., , Volume: 56, Issue:6, 2012
In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.Cancer biotherapy & radiopharmaceuticals, , Volume: 26, Issue:6, 2011
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 50, Issue:7, 2009
Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.Cancer biotherapy & radiopharmaceuticals, , Volume: 24, Issue:6, 2009
Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.European journal of nuclear medicine and molecular imaging, , Volume: 35, Issue:9, 2008
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.International journal of radiation oncology, biology, physics, , Oct-01, Volume: 69, Issue:2, 2007
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.Oncology reports, , Volume: 17, Issue:5, 2007
Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 66, Issue:4, 2006
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 46, Issue:12, 2005
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-01, Volume: 9, Issue:10 Pt 2, 2003
The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study.Acta oncologica (Stockholm, Sweden), , Volume: 39, Issue:6, 2000
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y.International journal of radiation oncology, biology, physics, , Volume: 10, Issue:3, 1984
Astatine-211--tellurium radiocolloid cures experimental malignant ascites.Science (New York, N.Y.), , Apr-17, Volume: 212, Issue:4492, 1981
Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.Anticancer research, , Volume: 20, Issue:1A
Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.Anticancer research, , Volume: 21, Issue:1A
In vitro effects of free 211At,211At-albumin and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines.Anticancer research, , Volume: 20, Issue:2A
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.International journal of radiation oncology, biology, physics, , Nov-01, Volume: 93, Issue:3, 2015
The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study.Acta oncologica (Stockholm, Sweden), , Volume: 39, Issue:6, 2000
Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model.Gynecologic oncology, , Volume: 47, Issue:3, 1992
Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters.International journal of radiation oncology, biology, physics, , Volume: 19, Issue:6, 1990
Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.Anticancer research, , Volume: 20, Issue:1A
Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.Anticancer research, , Volume: 21, Issue:1A
The development of a [211AT]-astatinated endoradiotherapeutic drug: part IV--late radiation effects.International journal of radiation oncology, biology, physics, , Mar-15, Volume: 40, Issue:5, 1998
The specific inhibition of cellular clonogenic proliferation using 211At labelled lectins and antibodies--I.International journal of nuclear medicine and biology, , Volume: 9, Issue:3, 1982
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology.European journal of nuclear medicine and molecular imaging, , Volume: 50, Issue:7, 2023
The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.European journal of nuclear medicine and molecular imaging, , Volume: 35, Issue:7, 2008
Synthesis and preliminary evaluation of Nuclear medicine and biology, , Volume: 94-95
The development of a [211At]-astatinated endoradiotherapeutic drug: Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies.International journal of radiation oncology, biology, physics, , Apr-30, Volume: 29, Issue:1, 1994
The development of A [211At]-astatinated endoradiotherapeutic drug: Part I. Localization by alpha-particle autoradiography in a murine tumor model.International journal of radiation oncology, biology, physics, , Volume: 23, Issue:3, 1992
Biodistribution of 6-[211At]astato-2-methyl-1,4-naphthoquinol bis(diphosphate salt) and 211At- in mice with a transplanted rectal adenocarcinoma.The International journal of applied radiation and isotopes, , Volume: 35, Issue:9, 1984
alpha-Particle track autoradiography for localization of a 211At-astatinated drug.Experientia, , Mar-15, Volume: 39, Issue:3, 1983
Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.British journal of cancer, , Volume: 77, Issue:7, 1998
Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.British journal of cancer, , Volume: 69, Issue:6, 1994
Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.Radiation research, , Volume: 139, Issue:2, 1994
Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies.Anticancer research, , Volume: 25, Issue:1A
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.European journal of nuclear medicine and molecular imaging, , Volume: 29, Issue:7, 2002
Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells.Nuclear medicine and biology, , Volume: 29, Issue:7, 2002
Assessing the 210At impurity in the production of 211At for radiotherapy by 210Po analysis via isotope dilution alpha spectrometry.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, , Volume: 64, Issue:10-11
Ionization chamber measurements of the half-lives of 24Na, 42K, 76As and 198Au.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, , Volume: 60, Issue:2-4
211At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage.European journal of cancer (Oxford, England : 1990), , Volume: 32A, Issue:11, 1996
Radioiodinated methylene blue for diagnosing early melanoma metastases.Lancet (London, England), , Sep-14, Volume: 348, Issue:9029, 1996
[211At]methylene blue for targeted radiotherapy of human melanoma xenografts: dose fractionation in the treatment of cutaneous tumours.European journal of cancer (Oxford, England : 1990), , Volume: 32A, Issue:7, 1996
211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases.Cancer research, , Aug-15, Volume: 52, Issue:16, 1992
Radioimmunotherapy with an Cancer science, , Volume: 112, Issue:5, 2021
Evidence of Local Concentration of α-Particles from Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 60, Issue:4, 2019
[Histopathological study of subcutaneous heterograft of human gastric cancer in nude mice treated with 211At labelled monoclonal antibody].Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 15, Issue:1, 1993
[The effect of 211At labelled monoclonal antibody against gastric cancer on DNA, RNA and protein synthesis in gastric cancer cell].Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, , Volume: 23, Issue:4, 1992
[Investigator-Initiated Clinical Trial of 211At-NaAt against Refractory Thyroid Cancer].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 49, Issue:8, 2022
Comparison of the Therapeutic Effects of [International journal of molecular sciences, , Aug-21, Volume: 23, Issue:16, 2022
Biodistribution of free 211At and 125I- in nude mice bearing tumors derived from anaplastic thyroid carcinoma cell lines.Cancer biotherapy & radiopharmaceuticals, , Volume: 21, Issue:6, 2006
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.European journal of nuclear medicine and molecular imaging, , Volume: 29, Issue:7, 2002
Endogenous 211At alpha-particle radiotherapy for undifferentiated thyroid cancer.Acta radiologica. Supplementum, , Volume: 376, 1991
Relative concentration of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, , Volume: 13, Issue:3, 1988
Astatine (211At) as a therapeutic radionuclide. The plasma:blood cell distribution in vitro.International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology, , Volume: 13, Issue:5, 1986
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.Cancer biotherapy & radiopharmaceuticals, , Volume: 20, Issue:5, 2005
High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate.Nuclear medicine and biology, , Volume: 28, Issue:1, 2001
Cell growth kinetics of the human cell line Colo-205 irradiated with photons and astatine-211 alpha-particles.Anticancer research, , Volume: 20, Issue:3A
Development of [Leukemia, , Volume: 36, Issue:6, 2022
Tumour localisation of 211At-labelled monoclonal antibody to a sub-cutaneous human heterograft in the nude mouse II.International journal of nuclear medicine and biology, , Volume: 10, Issue:4, 1983
The specific inhibition of cellular clonogenic proliferation using 211At labelled lectins and antibodies--I.International journal of nuclear medicine and biology, , Volume: 9, Issue:3, 1982
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.Blood, , 10-10, Volume: 134, Issue:15, 2019
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.International journal of radiation oncology, biology, physics, , Nov-01, Volume: 93, Issue:3, 2015
Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.Anticancer research, , Volume: 20, Issue:1A
[Investigator-Initiated Clinical Trial of 211At-NaAt against Refractory Thyroid Cancer].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 49, Issue:8, 2022
Comparison of the Therapeutic Effects of [International journal of molecular sciences, , Aug-21, Volume: 23, Issue:16, 2022
Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein.Nuclear medicine and biology, , Volume: 33, Issue:4, 2006
Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.Nuclear medicine and biology, , Volume: 31, Issue:8, 2004
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.European journal of nuclear medicine and molecular imaging, , Volume: 29, Issue:7, 2002
The development of a [211At]-astatinated endoradiotherapeutic drug: Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies.International journal of radiation oncology, biology, physics, , Apr-30, Volume: 29, Issue:1, 1994
Endogenous 211At alpha-particle radiotherapy for undifferentiated thyroid cancer.Acta radiologica. Supplementum, , Volume: 376, 1991
Tissue dose estimates following the selective uptake of 125IUdR and other radiolabelled thymidine precursors in resistant tumours.The British journal of radiology, , Volume: 64, Issue:757, 1991
Relative concentration of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, , Volume: 13, Issue:3, 1988
Biodistribution of 6-[211At]astato-2-methyl-1,4-naphthoquinol bis(diphosphate salt) and 211At- in mice with a transplanted rectal adenocarcinoma.The International journal of applied radiation and isotopes, , Volume: 35, Issue:9, 1984
alpha-Particle track autoradiography for localization of a 211At-astatinated drug.Experientia, , Mar-15, Volume: 39, Issue:3, 1983
Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention.Anticancer research, , Volume: 23, Issue:2B
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 49, Issue:1, 2008
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.European journal of nuclear medicine and molecular imaging, , Volume: 30, Issue:10, 2003
Radioimmunotherapy with an Cancer science, , Volume: 112, Issue:5, 2021
Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 58, Issue:4, 2017
Biological features of a transplantable Leydig cell tumor in rat.Gan, , Volume: 62, Issue:1, 1971
Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.European journal of nuclear medicine and molecular imaging, , Volume: 47, Issue:1, 2020
211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 40, Issue:7, 1999
Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.Radiation research, , Volume: 139, Issue:2, 1994
Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.British journal of cancer, , Volume: 69, Issue:6, 1994
Labeling Monoclonal Antibody with α-emitting Cancer biotherapy & radiopharmaceuticals, , Volume: 35, Issue:7, 2020
Systemic treatment with 4-211Atphenylalanine enhances survival of rats with intracranial glioblastoma.Nuklearmedizin. Nuclear medicine, , Dec-13, Volume: 52, Issue:6, 2013
Synthesis and analysis of 2-[211At]-L-phenylalanine and 4-[211At]-L-phenylalanine and their uptake in human glioma cell cultures in-vitro.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, , Volume: 68, Issue:6, 2010
Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.European journal of nuclear medicine and molecular imaging, , Volume: 35, Issue:9, 2008
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 49, Issue:1, 2008
Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 54, Issue:4, 2002
211At-alpha-dose dependence of poly-ADP-ribosylation of human glioblastoma cells in vitro. Suitability in cancer therapy?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], , Volume: 175, Issue:9, 1999
The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.Nuclear medicine and biology, , Volume: 43, Issue:1, 2016
The advantage of antibody cocktails for targeted alpha therapy depends on specific activity.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 55, Issue:12, 2014
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.Nuclear medicine and biology, , Volume: 36, Issue:6, 2009
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-01, Volume: 14, Issue:3, 2008
Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.Oncology reports, , Volume: 15, Issue:3, 2006
In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.Nuclear medicine and biology, , Volume: 33, Issue:3, 2006
Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.PloS one, , Volume: 10, Issue:5, 2015
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.Cancer biotherapy & radiopharmaceuticals, , Volume: 20, Issue:5, 2005
Relative concentration of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, , Volume: 13, Issue:3, 1988
Construction of a growth curve for mammary tumors of the rat.Cancer research, , Volume: 27, Issue:8, 1967
Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells.Anticancer research, , Volume: 24, Issue:6
Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.Anticancer research, , Volume: 20, Issue:1A
Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas.Nuclear medicine and biology, , Volume: 38, Issue:1, 2011
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 72, Issue:1, 2008
Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 67, Issue:1, 2007
Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.The Laryngoscope, , Volume: 117, Issue:6, 2007
In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.European journal of nuclear medicine and molecular imaging, , Volume: 32, Issue:11, 2005
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.European journal of nuclear medicine and molecular imaging, , Volume: 30, Issue:5, 2003
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.European journal of nuclear medicine and molecular imaging, , Volume: 30, Issue:10, 2003
Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.Cancer biotherapy & radiopharmaceuticals, , Volume: 29, Issue:6, 2014
Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein.Nuclear medicine and biology, , Volume: 33, Issue:4, 2006
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.Cancer biotherapy & radiopharmaceuticals, , Volume: 20, Issue:5, 2005
Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.Nuclear medicine and biology, , Volume: 31, Issue:8, 2004
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.European journal of nuclear medicine and molecular imaging, , Volume: 29, Issue:7, 2002
Tissue dose estimates following the selective uptake of 125IUdR and other radiolabelled thymidine precursors in resistant tumours.The British journal of radiology, , Volume: 64, Issue:757, 1991
Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay.Anticancer research, , Volume: 18, Issue:3A
Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention.Anticancer research, , Volume: 23, Issue:2B
In vitro effects of free 211At,211At-albumin and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines.Anticancer research, , Volume: 20, Issue:2A
Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.Cancer biotherapy & radiopharmaceuticals, , Volume: 29, Issue:6, 2014
Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.Cancer biotherapy & radiopharmaceuticals, , Volume: 28, Issue:2, 2013
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.Blood, , May-02, Volume: 121, Issue:18, 2013
Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.The Laryngoscope, , Volume: 117, Issue:6, 2007
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.Blood, , Aug-01, Volume: 108, Issue:3, 2006
[Therapy of malignant ascites in vivo by 211At-labelled microspheres].Nuklearmedizin. Nuclear medicine, , Volume: 43, Issue:2, 2004
Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.Nuclear medicine and biology, , Volume: 23, Issue:6, 1996
Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.Gynecologic oncology, , Volume: 57, Issue:1, 1995
Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2.Nuclear medicine and biology, , Volume: 20, Issue:8, 1993
Systemic treatment with 4-211Atphenylalanine enhances survival of rats with intracranial glioblastoma.Nuklearmedizin. Nuclear medicine, , Dec-13, Volume: 52, Issue:6, 2013
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 72, Issue:1, 2008
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 49, Issue:1, 2008
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.European journal of nuclear medicine and molecular imaging, , Volume: 29, Issue:7, 2002
Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 54, Issue:4, 2002
211At-alpha-dose dependence of poly-ADP-ribosylation of human glioblastoma cells in vitro. Suitability in cancer therapy?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], , Volume: 175, Issue:9, 1999
Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy.Journal of nanobiotechnology, , Jul-28, Volume: 19, Issue:1, 2021
Labeling Monoclonal Antibody with α-emitting Cancer biotherapy & radiopharmaceuticals, , Volume: 35, Issue:7, 2020
Synthesis and analysis of 2-[211At]-L-phenylalanine and 4-[211At]-L-phenylalanine and their uptake in human glioma cell cultures in-vitro.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, , Volume: 68, Issue:6, 2010
Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 67, Issue:1, 2007
In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 44, Issue:11, 2003
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.European journal of nuclear medicine and molecular imaging, , Volume: 30, Issue:5, 2003
Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells.Nuclear medicine and biology, , Volume: 29, Issue:7, 2002
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.Radiation research, , Volume: 149, Issue:2, 1998
Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.Nuclear medicine and biology, , Volume: 24, Issue:3, 1997
Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.International journal of radiation biology, , Volume: 72, Issue:1, 1997
Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide.Nuclear medicine and biology, , Volume: 22, Issue:4, 1995
Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.Proceedings of the National Academy of Sciences of the United States of America, , Volume: 86, Issue:18, 1989
The development of a [211AT]-astatinated endoradiotherapeutic drug: part IV--late radiation effects.International journal of radiation oncology, biology, physics, , Mar-15, Volume: 40, Issue:5, 1998
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma.NCI monographs : a publication of the National Cancer Institute, , Issue:3, 1987
Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.Medical physics, , Volume: 42, Issue:7, 2015
Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation.International journal of radiation biology, , Volume: 78, Issue:2, 2002
Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.British journal of cancer, , Volume: 83, Issue:10, 2000
Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 44, Issue:5, 2003
Biological features of a transplantable Leydig cell tumor in rat.Gan, , Volume: 62, Issue:1, 1971
Construction of a growth curve for mammary tumors of the rat.Cancer research, , Volume: 27, Issue:8, 1967
TUMOR INDUCTION WITH ASTATINE-211 IN RATS: CHARACTERIZATION OF PITUITARY TUMORS.Cancer research, , Volume: 24, 1964
Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers.Peptides, , Volume: 25, Issue:12, 2004
Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.Journal of neuro-oncology, , Volume: 25, Issue:1, 1995
Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor.Bioconjugate chemistry, , Volume: 17, Issue:1
Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience.Hybridoma, , Volume: 18, Issue:1, 1999
The survival of monolayers of cells growing in clusters irradiated by 211At appended to the cell surfaces.Radiation research, , Volume: 151, Issue:6, 1999
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.Radiation research, , Volume: 149, Issue:2, 1998
Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.International journal of radiation biology, , Volume: 72, Issue:1, 1997
Radioiodinated methylene blue for diagnosing early melanoma metastases.Lancet (London, England), , Sep-14, Volume: 348, Issue:9029, 1996
[211At]methylene blue for targeted radiotherapy of human melanoma xenografts: dose fractionation in the treatment of cutaneous tumours.European journal of cancer (Oxford, England : 1990), , Volume: 32A, Issue:7, 1996
211At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage.European journal of cancer (Oxford, England : 1990), , Volume: 32A, Issue:11, 1996
Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide.Nuclear medicine and biology, , Volume: 22, Issue:4, 1995
Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.British journal of cancer, , Volume: 69, Issue:6, 1994
211At-methylene blue in targeted radiotherapy of disseminated melanoma.Pigment cell research, , Volume: 7, Issue:5, 1994
211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases.Cancer research, , Aug-15, Volume: 52, Issue:16, 1992
211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases.Cancer research, , May-15, Volume: 50, Issue:10, 1990
Astatine-211: its possible applications in cancer therapy.International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes, , Volume: 37, Issue:8, 1986
Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-astatobenzoate: comparisons in vivo with the p-[125I]iodobenzoyl conjugate.Bioconjugate chemistry, , Volume: 2, Issue:3
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.Cancer research, , Sep-01, Volume: 54, Issue:17, 1994
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.Blood, , May-02, Volume: 121, Issue:18, 2013
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.Cancer biotherapy & radiopharmaceuticals, , Volume: 20, Issue:5, 2005
Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.Australasian radiology, , Volume: 43, Issue:4, 1999
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases.Cancer research, , May-15, Volume: 50, Issue:10, 1990
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology.European journal of nuclear medicine and molecular imaging, , Volume: 50, Issue:7, 2023
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , 09-15, Volume: 28, Issue:18, 2022
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.International journal of radiation oncology, biology, physics, , Nov-01, Volume: 93, Issue:3, 2015
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 49, Issue:1, 2008
[no title available]Molecular pharmaceutics, , 09-06, Volume: 18, Issue:9, 2021
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.Cancer biotherapy & radiopharmaceuticals, , Volume: 35, Issue:6, 2020
An Appendix of Radionuclides Used in Targeted Alpha Therapy.Journal of medical imaging and radiation sciences, , Volume: 50, Issue:4 Suppl 1, 2019
Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 59, Issue:4, 2018
Astatine-211 imaging by a Compton camera for targeted radiotherapy.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, , Volume: 139, 2018
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Expert opinion on biological therapy, , Volume: 16, Issue:8, 2016
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.Scientific reports, , Jul-14, Volume: 5, 2015
Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.Cancer biotherapy & radiopharmaceuticals, , Volume: 28, Issue:1, 2013
The ARRONAX project.Current radiopharmaceuticals, , Volume: 4, Issue:3, 2011
Effect of different cell cluster models on the radiobiological output for (211)At-radioimmunotherapy.Cancer biotherapy & radiopharmaceuticals, , Volume: 26, Issue:1, 2011
Astatine-211: production and availability.Current radiopharmaceuticals, , Volume: 4, Issue:3, 2011
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.Current radiopharmaceuticals, , Volume: 4, Issue:4, 2011
Evaluating 99mTc Auger electrons for targeted tumor radiotherapy by computational methods.Medical physics, , Volume: 37, Issue:7, 2010
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.Nuclear medicine and biology, , Volume: 34, Issue:7, 2007
Potential and pitfalls of therapy with alpha-particles.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 46, Issue:8, 2005
External targets for the production of 211At--review and status of the target development at the Hannover cyclotron.Zeitschrift fur medizinische Physik, , Volume: 14, Issue:3, 2004
A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides.Acta oncologica (Stockholm, Sweden), , Volume: 43, Issue:3, 2004
Radioimmunotherapy with alpha-particle emitting radionuclides.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., , Volume: 48, Issue:4, 2004
Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.European journal of nuclear medicine, , Volume: 28, Issue:4, 2001
Advancements in cancer therapy with alpha-emitters: a review.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 51, Issue:1, 2001
Overcoming the obstacles to clinical evaluation of (211)At-labeled radiopharmaceuticals.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 42, Issue:10, 2001
Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.Current pharmaceutical design, , Volume: 6, Issue:14, 2000
Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.Australasian radiology, , Volume: 43, Issue:4, 1999
Genetic enhancement of radionuclide cancer therapy.Lancet (London, England), , Dec-04, Volume: 354, Issue:9194, 1999
Targeted therapy using alpha emitters.Physics in medicine and biology, , Volume: 41, Issue:10, 1996
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, , Volume: 141, 1996
Steps towards cancer therapy with radionuclides--a review including radiation biophysical aspects.Radiobiologia, radiotherapia, , Volume: 31, Issue:3, 1990
A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy.International journal of radiation oncology, biology, physics, , Volume: 13, Issue:11, 1987
Astatine-211: its possible applications in cancer therapy.International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes, , Volume: 37, Issue:8, 1986
Therapeutic applications of Auger and alpha emitting radionuclides.Strahlentherapie, , Volume: 160, Issue:12, 1984
Radioactive derivatives of 2-methyl-1, 4-naphthoquinol bis (diphosphate salt) as anti-cancer drugs with high LET radiations.Progress in clinical and biological research, , Volume: 166, 1984
Radiation biology and potential therapeutic applications of radionuclides.Bulletin du cancer, , Volume: 67, Issue:3, 1980
Potential future application with therapeutic agents.Seminars in nuclear medicine, , Volume: 9, Issue:2, 1979
TUMOR INDUCTION WITH ASTATINE-211 IN RATS: CHARACTERIZATION OF PITUITARY TUMORS.Cancer research, , Volume: 24, 1964
The induction of tumors in the rat by astatine-211.Radiation research, , Volume: 9, Issue:3, 1958
[Leukemia & lymphoma, , Volume: 64, Issue:7
1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.Bioconjugate chemistry, , Volume: 3, Issue:6
Two ways to establish potential At-211 radiopharmaceuticals.Anticancer research, , Volume: 17, Issue:3B
Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives.Bioconjugate chemistry, , Volume: 15, Issue:3
Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.Bioconjugate chemistry, , Jun-15, Volume: 22, Issue:6, 2011
Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors.Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-15, Volume: 12, Issue:4, 2006
(211)At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-01, Volume: 9, Issue:10 Pt 2, 2003
Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.Nuclear medicine and biology, , Volume: 26, Issue:4, 1999
The development of a [211At]-astatinated endoradiotherapeutic drug: Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies.International journal of radiation oncology, biology, physics, , Apr-30, Volume: 29, Issue:1, 1994
[Animal experimental studies on the biokinetics of astatide and astato-(I)-complex compounds].Radiobiologia, radiotherapia, , Volume: 27, Issue:4, 1986
alpha-Particle track autoradiography for localization of a 211At-astatinated drug.Experientia, , Mar-15, Volume: 39, Issue:3, 1983
Astatine-211--tellurium radiocolloid cures experimental malignant ascites.Science (New York, N.Y.), , Apr-17, Volume: 212, Issue:4492, 1981
Potential future application with therapeutic agents.Seminars in nuclear medicine, , Volume: 9, Issue:2, 1979
TUMOR INDUCTION WITH ASTATINE-211 IN RATS: CHARACTERIZATION OF PITUITARY TUMORS.Cancer research, , Volume: 24, 1964
The induction of tumors in the rat by astatine-211.Radiation research, , Volume: 9, Issue:3, 1958
Astatine-211-induced transplantatble pituitary tumor in the rat with a brief analytic review of cell types of pituitary tumors.The American journal of pathology, , Volume: 51, Issue:4, 1967
Construction of a growth curve for mammary tumors of the rat.Cancer research, , Volume: 27, Issue:8, 1967
TUMOR INDUCTION WITH ASTATINE-211 IN RATS: CHARACTERIZATION OF PITUITARY TUMORS.Cancer research, , Volume: 24, 1964
Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 58, Issue:4, 2017
Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.PloS one, , Volume: 10, Issue:5, 2015
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.International journal of radiation oncology, biology, physics, , Nov-01, Volume: 93, Issue:3, 2015
Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.Cancer biotherapy & radiopharmaceuticals, , Volume: 28, Issue:2, 2013
Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., , Volume: 56, Issue:6, 2012
In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.Cancer biotherapy & radiopharmaceuticals, , Volume: 26, Issue:6, 2011
Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.Cancer biotherapy & radiopharmaceuticals, , Volume: 24, Issue:6, 2009
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 50, Issue:7, 2009
Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.European journal of nuclear medicine and molecular imaging, , Volume: 35, Issue:9, 2008
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.International journal of radiation oncology, biology, physics, , Oct-01, Volume: 69, Issue:2, 2007
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.Oncology reports, , Volume: 17, Issue:5, 2007
Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 66, Issue:4, 2006
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 46, Issue:12, 2005
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-01, Volume: 9, Issue:10 Pt 2, 2003
The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study.Acta oncologica (Stockholm, Sweden), , Volume: 39, Issue:6, 2000
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.Acta oncologica (Stockholm, Sweden), , Volume: 35, Issue:3, 1996
211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y.International journal of radiation oncology, biology, physics, , Volume: 10, Issue:3, 1984
Astatine-211--tellurium radiocolloid cures experimental malignant ascites.Science (New York, N.Y.), , Apr-17, Volume: 212, Issue:4492, 1981
Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.Anticancer research, , Volume: 21, Issue:1A
In vitro effects of free 211At,211At-albumin and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines.Anticancer research, , Volume: 20, Issue:2A
Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.Anticancer research, , Volume: 20, Issue:1A
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.International journal of radiation oncology, biology, physics, , Nov-01, Volume: 93, Issue:3, 2015
The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study.Acta oncologica (Stockholm, Sweden), , Volume: 39, Issue:6, 2000
Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model.Gynecologic oncology, , Volume: 47, Issue:3, 1992
Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters.International journal of radiation oncology, biology, physics, , Volume: 19, Issue:6, 1990
Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.Anticancer research, , Volume: 21, Issue:1A
Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.Anticancer research, , Volume: 20, Issue:1A
The development of a [211AT]-astatinated endoradiotherapeutic drug: part IV--late radiation effects.International journal of radiation oncology, biology, physics, , Mar-15, Volume: 40, Issue:5, 1998
The specific inhibition of cellular clonogenic proliferation using 211At labelled lectins and antibodies--I.International journal of nuclear medicine and biology, , Volume: 9, Issue:3, 1982
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology.European journal of nuclear medicine and molecular imaging, , Volume: 50, Issue:7, 2023
The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.European journal of nuclear medicine and molecular imaging, , Volume: 35, Issue:7, 2008
Synthesis and preliminary evaluation of Nuclear medicine and biology, , Volume: 94-95
(211)At-antiCD33 in NMRI nu/nu mice. Biodistribution, in vivo stability and radiotoxicity.Nuklearmedizin. Nuclear medicine, , Volume: 50, Issue:5, 2011
Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 46, Issue:3, 2005
211At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage.European journal of cancer (Oxford, England : 1990), , Volume: 32A, Issue:11, 1996
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.Cancer research, , Mar-15, Volume: 69, Issue:6, 2009
The development of a [211AT]-astatinated endoradiotherapeutic drug: part IV--late radiation effects.International journal of radiation oncology, biology, physics, , Mar-15, Volume: 40, Issue:5, 1998
Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds.Nuclear medicine and biology, , Volume: 25, Issue:4, 1998
The development of a [211At]-astatinated endoradiotherapeutic drug: Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies.International journal of radiation oncology, biology, physics, , Apr-30, Volume: 29, Issue:1, 1994
The development of A [211At]-astatinated endoradiotherapeutic drug: Part I. Localization by alpha-particle autoradiography in a murine tumor model.International journal of radiation oncology, biology, physics, , Volume: 23, Issue:3, 1992
Biodistribution of 6-[211At]astato-2-methyl-1,4-naphthoquinol bis(diphosphate salt) and 211At- in mice with a transplanted rectal adenocarcinoma.The International journal of applied radiation and isotopes, , Volume: 35, Issue:9, 1984
alpha-Particle track autoradiography for localization of a 211At-astatinated drug.Experientia, , Mar-15, Volume: 39, Issue:3, 1983
Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.British journal of cancer, , Volume: 77, Issue:7, 1998
Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.Radiation research, , Volume: 139, Issue:2, 1994
Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.British journal of cancer, , Volume: 69, Issue:6, 1994
Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies.Anticancer research, , Volume: 25, Issue:1A
211At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage.European journal of cancer (Oxford, England : 1990), , Volume: 32A, Issue:11, 1996
[211At]methylene blue for targeted radiotherapy of human melanoma xenografts: dose fractionation in the treatment of cutaneous tumours.European journal of cancer (Oxford, England : 1990), , Volume: 32A, Issue:7, 1996
Radioiodinated methylene blue for diagnosing early melanoma metastases.Lancet (London, England), , Sep-14, Volume: 348, Issue:9029, 1996
211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases.Cancer research, , Aug-15, Volume: 52, Issue:16, 1992
Radioimmunotherapy with an Cancer science, , Volume: 112, Issue:5, 2021
Evidence of Local Concentration of α-Particles from Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 60, Issue:4, 2019
[Histopathological study of subcutaneous heterograft of human gastric cancer in nude mice treated with 211At labelled monoclonal antibody].Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 15, Issue:1, 1993
[The effect of 211At labelled monoclonal antibody against gastric cancer on DNA, RNA and protein synthesis in gastric cancer cell].Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, , Volume: 23, Issue:4, 1992
Comparison of the Therapeutic Effects of [International journal of molecular sciences, , Aug-21, Volume: 23, Issue:16, 2022
[Investigator-Initiated Clinical Trial of 211At-NaAt against Refractory Thyroid Cancer].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 49, Issue:8, 2022
Biodistribution of free 211At and 125I- in nude mice bearing tumors derived from anaplastic thyroid carcinoma cell lines.Cancer biotherapy & radiopharmaceuticals, , Volume: 21, Issue:6, 2006
Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.European journal of nuclear medicine and molecular imaging, , Volume: 29, Issue:7, 2002
Endogenous 211At alpha-particle radiotherapy for undifferentiated thyroid cancer.Acta radiologica. Supplementum, , Volume: 376, 1991
Relative concentration of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, , Volume: 13, Issue:3, 1988
Astatine (211At) as a therapeutic radionuclide. The plasma:blood cell distribution in vitro.International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology, , Volume: 13, Issue:5, 1986
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.Cancer biotherapy & radiopharmaceuticals, , Volume: 20, Issue:5, 2005
High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate.Nuclear medicine and biology, , Volume: 28, Issue:1, 2001
Cell growth kinetics of the human cell line Colo-205 irradiated with photons and astatine-211 alpha-particles.Anticancer research, , Volume: 20, Issue:3A
Development of [Leukemia, , Volume: 36, Issue:6, 2022
Tumour localisation of 211At-labelled monoclonal antibody to a sub-cutaneous human heterograft in the nude mouse II.International journal of nuclear medicine and biology, , Volume: 10, Issue:4, 1983
The specific inhibition of cellular clonogenic proliferation using 211At labelled lectins and antibodies--I.International journal of nuclear medicine and biology, , Volume: 9, Issue:3, 1982
Safety/Toxicity (11)
| Article | Year |
|---|
(211)At-antiCD33 in NMRI nu/nu mice. Biodistribution, in vivo stability and radiotoxicity.
Nuklearmedizin. Nuclear medicine, , Volume: 50, Issue:5 | 2011 |
In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
Nuclear medicine and biology, , Volume: 33, Issue:3 | 2006 |
Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 46, Issue:3 | 2005 |
In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 44, Issue:11 | 2003 |
Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.
British journal of cancer, , Volume: 83, Issue:10 | 2000 |
Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.
International journal of radiation oncology, biology, physics, , Sep-01, Volume: 45, Issue:2 | 1999 |
Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
British journal of cancer, , Volume: 77, Issue:12 | 1998 |
Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
British journal of cancer, , Volume: 77, Issue:5 | 1998 |
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
Radiation research, , Volume: 149, Issue:2 | 1998 |
Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.
International journal of radiation biology, , Volume: 72, Issue:1 | 1997 |
Toxicity of astatine-211 in the mouse.
Human toxicology, , Volume: 7, Issue:6 | 1988 |
Pharmacokinetics (1)
Dosage (9)
| Article | Year |
|---|
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, , 09-15, Volume: 28, Issue:18 | 2022 |
Effect of different cell cluster models on the radiobiological output for (211)At-radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals, , Volume: 26, Issue:1 | 2011 |
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
International journal of radiation oncology, biology, physics, , Oct-01, Volume: 69, Issue:2 | 2007 |
An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
The journal of gene medicine, , Volume: 6, Issue:8 | 2004 |
[Therapy of malignant ascites in vivo by 211At-labelled microspheres].
Nuklearmedizin. Nuclear medicine, , Volume: 43, Issue:2 | 2004 |
Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.
British journal of cancer, , Volume: 77, Issue:7 | 1998 |
A model of cell inactivation by alpha-particle internal emitters.
Radiation research, , Volume: 134, Issue:2 | 1993 |
[Histopathological study of subcutaneous heterograft of human gastric cancer in nude mice treated with 211At labelled monoclonal antibody].
Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 15, Issue:1 | 1993 |
Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model.
Gynecologic oncology, , Volume: 47, Issue:3 | 1992 |
Interactions (2)